SALVAGE TREATMENT OF UNFAVORABLE NON-HODGKINS-LYMPHOMA WITH CISPLATIN, AMSACRINE, AND MITOGUAZONE - A SOUTHWEST ONCOLOGY GROUP PILOT-STUDY

  • 1 February 1986
    • journal article
    • research article
    • Vol. 70  (2) , 291-292
Abstract
We tested the combination of cisplatin, amsacrine, and mitoguazone as salvage treatment for patients with advanced unfavorable non-Hodgkin''s lymphomas. An objective response rate of 43% was noted in 30 evaluable patients, but all responses were partial and the median duration of response was only 2 months. Toxicity included life-threatening and fatal leukopenia and severe gastrointestinal intolerance. We conclude that this combination chemotherapy regimen is not a valuable salvage treatment for patients with non-Hodgkin''s lymphoma.